Balaji Amines Ltd

- Phase-2 Greenfield project CAPEX planned for FY23 and FY24 is Rs. 300 to 400 crores. - Four new plants being installed under this phase: - N-Butylamine plant with 15,000 tons capacity. - Acetonitrile plant with 15,000 tons capacity. - Methylamine plant with 40,000 tons capacity. - DMF plant with 30,000 tons capacity. - Production at these plants expected to commence between mid FY24 and end of FY25. - Majority of the CAPEX funding will be from internal accruals; minor borrowing possible towards project completion. - Plans to expand and diversify the product portfolio with new products like DMC and propylene glycol. - The company is also evaluating debottlenecking and potential derivatives addition at subsidiaries to grow capacity further.

- The company conservatively forecasts revenue of Rs. 2,500 crores for the next year, factoring in potential price declines although EBITDA and EPS are expected to remain stable. (Page 15) - Full capacity utilization of existing and new plants (N-Butyl Amine, Acetonitrile, Methylamine, DMF) is expected by end of FY25, targeting a revenue of around Rs. 4,000 crores. (Page 14) - FY23 standalone revenue is guided between Rs. 2,200 to Rs. 2,300 crores; consolidated revenue should reach Rs. 2,500 crores. (Page 12) - Subsidiary's turnover expected to grow to Rs. 700-750 crores in FY23, with capacity utilization rising to 70%-80%. (Page 4) - Volumes are anticipated to grow annually by approximately 10%-15%, with total volumes projected to exceed 1,15,000 metric tons. (Page 8) - New products like DMC and Propylene Glycol expected to add Rs. 300 crores in revenue once fully operational. (Page 9) - Export revenue share aimed to increase to 30%-35% of total revenues to mitigate risks related to imported raw materials. (Page 9)

- Revenue guidance for FY23 is conservative at Rs. 2,500 crores, considering potential price corrections but new products adding to sales. - Despite conservative revenue guidance, absolute EBITDA and EPS values are expected to remain stable. - EBITDA margin guidance for FY23 is maintained at 24% to 26%, with potential short-term dip during new product market entries but expected recovery thereafter. - Expansion includes four new plants (N-Butyl amine, Acetonitrile, Methylamine, DMF) to be commissioned by end of 2025, targeting a top-line of Rs. 4,000 crores by then. - Strong growth potential anticipated due to 'China Plus One' policy boosting Indian pharma and agrochemical sectors, end-user markets of their specialty chemicals. - Volumes and capacity utilization expected to improve, supporting sustainable earnings growth. - The company expects to maintain around 30%-35% of revenue from exports, expanding the market base and earnings.

- The transcript provided in the document "380.pdf" does not explicitly mention the current or expected order book or pending orders for Balaji Amines Limited. - However, the company discusses capacity additions, new product launches, and growth expectations indicating a strong demand environment. - Ram Reddy mentioned commissioning four new plants (N-Butyl amine, Acetonitrile, Methylamine, DMF) expected by end of 2025 implying anticipated orders to utilize these capacities. - The management is confident about future growth with revenue guidance of Rs. 2,500 crores for the next year, aiming Rs. 4,000 crores post capacity expansion. - Strong demand is noted in end-user industries with continued growth potential, backed by ‘China plus one’ strategy. - No specific order book or pending order details were disclosed in the transcript.

- Majority of the planned CAPEX will be funded through internal accruals. - A few crores of borrowing might be considered toward the end of the completion phase if required. - There is a credit committee in the subsidiary board evaluating options including possible mergers, but no specific mention of fresh equity fundraising. - No explicit plans for equity fundraising were disclosed in the provided transcript. - Overall, the company appears focused on utilizing internal funds with limited external borrowing potential for near-term investments.